Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Procter & Gamble CFO Andre Schulten Sells $5.18M of Stock
Andre Schulten, CFO, sold 30,677 shares of Procter & Gamble Co at $169.00 a share, worth $5.18M in total on Nov 5, 2026. Shares held after the trade: 65,618 (-31.9%).
Procter & Gamble CEO - Grooming de Azevedo Juliana Monteiro Santos Sells $908K of Stock
de Azevedo Juliana Monteiro Santos, CEO - Grooming, sold 5,370 shares of Procter & Gamble Co at $169.00 a share, worth $908K in total on Nov 5, 2026. Shares held after the trade: 21,361 (-20.1%).
Ttm Technologies Director Philip G. Franklin Buys $310K of Stock
Philip G. Franklin, Director, bought 5,000 shares of Ttm Technologies Inc at $61.92 a share, worth $310K in total on Nov 5, 2026. Shares held after the trade: 161,725 (+3.2%).
Muzinich Corporate Lending Income Fund Capital Raise of $3M
Muzinich Corporate Lending Income Fund, Inc. sold 2,909.57 shares of common stock in an unregistered private placement for aggregate proceeds of $3.0 million. The shares were priced at $1,031.08 per share and issued to accredited investors under Section 4(a)(2) and Regulation D exemptions.
Claritev Corporation reported a net loss of $61.8 million for the third quarter of 2026, an improvement from the $69.8 million loss in the prior year period, driven by a 9% increase in revenues to $268.3 million. Despite higher operating income, the company remains heavily burdened by $100.9 million in quarterly interest expense and carries a total shareholders' deficit of $339.9 million.
WF Card Issuance Trust, a vehicle of Wells Fargo Bank, announced it expects to issue Class A(2026-2) Notes on November 12, 2026. The company entered into an underwriting agreement and terms agreement on November 5, 2026, for the issuance of these asset-backed securities.
Oppenheimer Holdings' subsidiary Viner Finance entered into a 15.5-year lease for approximately 221,339 square feet at 32 Old Slip in Lower Manhattan to serve as its new principal headquarters. The relocation involves a $66 million investment and will house executive management, research, trading, and investment banking operations starting in early 2028. The agreement includes fixed annual rent starting at $13.3 million and provides for significant capital expenditures for technology and infrastructure upgrades.
Telos delivered a significant Q3 beat and raised full-year guidance, driven by strong Exacta AI adoption and TSA PreCheck performance despite a 2027 revenue headwind.
CNH Industrial is transitioning to a pure-play agriculture company by divesting 70% of its construction business to Kobelco for $1 billion while managing a challenging agricultural cycle with mixed regional demand.
Cincinnati Financial Corporation has posted a formal investor presentation deck to its website for use in meetings beginning November 10, 2026. The presentation outlines the company's long-term strategy, including a target Value Creation Ratio (VCR) of 10% to 13% over the next five-year period. Key performance drivers highlighted include premium growth above industry averages and a target combined ratio between 92% and 98%.
CECO delivered record Q3 results with revenue doubling to $404 million, driven by the Thermon acquisition and 30% organic growth, while providing aggressive 2027 guidance.
Turning Point Brands is aggressively pivoting to Modern Oral products, with 103% net sales growth in that segment offsetting declines in Zig-Zag rolling papers.
For the quarter ended September 30, 2026, CNH Industrial reported total revenues of $4.35 billion, a slight decrease from $4.40 billion in the prior year. Net income attributable to the company fell to $30 million ($0.02 per share) compared to $80 million ($0.06 per share) in 2025, primarily impacted by a significantly higher income tax expense during the period.
Provident Financial Holdings Insider Craig G. Blunden Sells $104K of Stock
Craig G. Blunden sold 5,700 shares of Provident Financial Holdings Inc at $18.20 a share, worth $104K in total on Nov 5, 2026. Shares held after the trade: 202,284 (-2.7%).
Regions Financial Corporation reported 848,847,340 shares of common stock outstanding as of November 6, 2026. The filing outlines significant risk factors including market interest rate fluctuations, credit losses, and potential weaknesses in residential and commercial real estate markets.
Monroe Capital Enhanced Corporate Lending Fund Capital Raise
Monroe Capital Enhanced Corporate Lending Fund completed private offerings of Class S and Class D common shares along with promissory notes to 110 accredited investors, raising approximately $152,000 in net proceeds. In connection with these offerings, the Fund reached its minimum shareholder threshold and terminated its existing escrow agreement with U.S. Bank and other parties as the escrow arrangement was no longer required.
Golden Growers Cooperative reported net income of $4.2 million for the nine months ended September 30, 2026, a slight decrease from $4.5 million in the prior year. The Cooperative's financial position remains influenced by its 50% interest in ProGold LLC, which contributed $4.67 million in net income during the period, while members' equity decreased to $13.6 million following $10.7 million in distributions.
Village Farms delivered record cannabis revenues of $55 million and 27% adjusted EBITDA margins, driven by 75% international export growth despite Canadian trim pricing headwinds and supply constraints awaiting Delta 2 expansion.
Trinseo PLC filed for Chapter 11 bankruptcy on May 26, 2026, to facilitate a comprehensive capital restructuring. As of September 30, 2026, the company reported total assets of $2,456.6 million and a significant increase in short-term borrowings and current debt to $589.6 million compared to $212.9 million at year-end 2025.
Orthofix reported a challenging Q3 2026, missing internal expectations due to US Spine market softness and supplier delays, leading to a downward revision of full-year revenue and EBITDA guidance.
Oncolytics Biotech announced translational data from a Phase 1b/2 trial evaluating pelareorep in patients with relapsed/refractory multiple myeloma. Single-cell sequencing demonstrated that pelareorep engaged the immune system, remodeled the tumor microenvironment, and increased populations of CD8 effector memory T cells. The data, which showed greater T cell expansion in clinical responders, will be presented at the 68th ASH Annual Meeting.
ChoiceOne Financial Services reported net income of $40.7 million for the first nine months of 2026, a significant increase from $14.3 million in the same period of 2025, which was impacted by $17.4 million in merger-related expenses. Total assets grew slightly to $4.46 billion, while the company experienced a notable increase in accumulated other comprehensive loss due to unrealized losses on available-for-sale securities.
Cullen/Frost Bankers President of CFR Paul Bracher Sells $459K of Stock
Paul Bracher, President of CFR, sold 2,900 shares of Cullen/Frost Bankers, Inc. at $158.24 a share, worth $459K in total on Nov 5, 2026. Shares held after the trade: 108,736 (-2.6%).
Crexendo, Inc. has posted an updated investor presentation to its website and filed it as an exhibit to this 8-K. The presentation, dated November 2026, provides a strategic and operational overview of the company for investors and analysts.
Exascale Labs Holdings Inc. entered into a firm order to purchase 16 Intel BHS 10U GPU servers equipped with NVIDIA HGX B300 GPUs from Compal Electronics for $9.04 million. The purchase is part of a larger framework agreement allowing the company to acquire up to 128 servers for a total potential value of $72.32 million through March 2027. This acquisition represents a material investment in the company's physical high-performance computing infrastructure.
Werewolf Therapeutics announced new clinical data from its Phase 1/1b trial of WTX-124 and Phase 1b/2 trial of WTX-330 for the treatment of solid tumors at the SITC 2026 Annual Meeting. WTX-124 demonstrated durable antitumor activity, including a complete response in a patient with cutaneous squamous cell carcinoma, and the company aligned with the FDA on a recommended Phase 2 dose of 18 mg. WTX-330 was reported as well-tolerated with evidence of monotherapy clinical activity in advanced, treatment-refractory disease.
Nkarta announced positive initial clinical data from its Ntrust program evaluating NKX019, an allogeneic CAR NK cell therapy, for myositis and systemic sclerosis. In the 4 billion cells per dose cohort, 83% of myositis patients achieved moderate or major responses, while 86% of systemic sclerosis patients achieved an rCRISS-25 response or greater. The therapy demonstrated a favorable safety profile with no cases of CRS, ICANS, or GvHD across 40 treated patients.
TMC's subsidiary received notification from NOAA regarding the expected timeline for a certification determination on its deep seabed exploration and commercial recovery application. NOAA expects to provide its final determination by mid-December 2026, which serves as an intermediate step in the regulatory review process under the Deep Seabed Hard Mineral Resources Act.
Surgery Partners Signs $6B M&A Deal with HealthSpan Partners
Surgery Partners entered into an amendment to its merger agreement with HealthSpan Partners (an affiliate of Bon Secours Mercy Health), increasing the cash consideration to $25.00 per share. The deal includes a 'ticking fee' of up to $1.61 per share if closing is delayed past March 1, 2027, bringing the total enterprise value to approximately $6.0 billion. The amendment follows an unsolicited $28.00 per share competing proposal from a third party, which the board determined was less favorable due to regulatory and closing certainty provided by HealthSpan.
Value
$6B
Counterparty
HealthSpan Partners
“We are pleased to have reached this outcome, which reflects the rigorous focus of our Board of Directors and Special Committee throughout this process on delivering the best possible result for Surgery Partners and our stockholders. This transaction provides exceptional value for our stockholders, along with regulatory certainty and a closing expected in the near term.”
Eric Evans, Chief Executive Officer of Surgery Partners
Fox Corporation completed the acquisition of Roku, Inc. on November 6, 2026, for a combination of cash and FOX Class A Common Stock. This filing provides the required historical financial statements of Roku and pro forma financial information following the consummation of the transaction. Fox expects to realize synergies and operational efficiencies from the integration of Roku's streaming platform into its media business.